- OTIC +114% on Q3 result.
- CALL +50%.
- KBSF +49%.
- SAGE +46% on late-stage success with brexanolone propels Marinus Pharma.
- CVO +42% on $61M U.S. Census contract award.
- ROKU +29% on Q3 result.
- ARLZ +20% on Q3 result.
- MRNS +20% on late-stage success with brexanolone propels Marinus Pharma.
- UEC +18%.
- OSTK +15% on Q3 result.
- COTY +14% on Q3 result.
- PRTY +12% on Q3 result.
- KNDI +12% on Q result.
- PRGO +12% on Q3 result.
- SEDG +11%.
- NQ +8% on the FL Mobile divestment and the sale of Showself's live social video business.
- NOG +8% on Q3 result.
- ODP +7% on Q3 result.
- IOVA +7% on early efficacy and safety data from Cohort 2 of the ongoing Phase 2 LN-144 metastatic melanoma trial.
- GOOS +6% on Q3 result.
- SMI +6%.
- EVOK +5% on signing commercial agreement with Thermo Fisher Scientific.